Alvogen Korea, a subsidiary of the global pharmaceutical group Lotus, is steadily growing as a leading specialty pharmaceutical company. Leveraging its expertise in obesity, central nervous system, renal, and cardiovascular therapies, Alvogen Korea has established a strong presence in the domestic specialty medicine market. By combining accumulated expertise with the strength of a global network, we continuously enhance our competitiveness.
Through rigorous quality management, a reliable supply system, and close collaboration with domestic and international partners, we deliver medicines that meet global standards. Guided by professionalism and ethical management, we are committed to improving patients’ quality of life and advancing public health.
Looking ahead, Alvogen Korea is committed to leading the future of the pharmaceutical industry through sustainable growth.
Through rigorous quality management, a reliable supply system, and close collaboration with domestic and international partners, we deliver medicines that meet global standards. Guided by professionalism and ethical management, we are committed to improving patients’ quality of life and advancing public health.
Looking ahead, Alvogen Korea is committed to leading the future of the pharmaceutical industry through sustainable growth.
